Form 4: Regulus Therapeutics Director William Rastetter Acquires 60,000 Stock Options

Director William Rastetter acquired 60,000 stock options in Regulus Therapeutics Inc. on May 20, 2024.

Summary

• William H Rastetter, a director of Regulus Therapeutics Inc., acquired 60,000 stock options on May 20, 2024.
• The exercise price of these options is $2.01.
• The options vest ratably over twelve months, becoming fully vested one year after the grant date or at the next annual shareholder meeting, contingent upon continuous service.
• The expiration date for these options is May 19, 2034.
• Rastetter also indirectly owns 60,000 derivative securities through the Rastetter Family Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider transactions can sometimes indicate sentiment, this is a routine grant.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options is contingent upon the Reporting Person's continuous service, suggesting an incentive for continued involvement with the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could positively influence shareholder sentiment, reflecting confidence in the company's prospects.

Key Dates